Pluvicto, a prostate cancer drug, has gained expanded approval that triples the number of patients with metastatic disease ...
Janux Therapeutics' lead drug, JANX007, shows promising prostate cancer results with no serious side effects. Find out why ...
The radioligand agent is now approved for use before chemotherapy in patients who have been treated with an androgen receptor ...
The radiopharmaceutical lutetium 177 can be used after radium 223 to treat metastatic castration-resistant prostate cancer.
The FDA approved several therapies in oncology in the month of March 2025. These drugs included treatments for ...
After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much ...
The FDA has expanded the approval for Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to include patients with PSMA-positive mCRPC who have been treated with ARPI therapy and can delay chemotherapy.
The antibody-drug conjugate FOR46 showed the strong potential of using CD46 as a new therapeutic target in metastatic ...
The U.S. Food and Drug Administration (FDA) on Friday approved Novartis AG’s NVS Pluvicto for prostate cancer patients. The expanded indication, which approximately triples the number of patients ...
Novartis (NVS) announced that the Food and Drug Administration approved Pluvicto for patients with prostate-specific membrane antigen-positive ...
Novartis (NOVN: VX) announced late Friday that the US Food and Drug Administration (FDA) approved Pluvicto (lutetium Lu 177 ...
The Food and Drug Administration (FDA) has expanded the approval of Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) to include patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback